TY - JOUR
T1 - Results of patch testing with five fragrance materials hitherto not tested
T2 - A dose-finding study in the clinical population
AU - Sukakul, Thanisorn
AU - Uter, Wolfgang
AU - Gonçalo, Margarida
AU - Huggard, Joseph
AU - Ljubojević Hadžavdić, Suzana
AU - Schuttelaar, Marie L. A.
AU - Svedman, Cecilia
AU - Vey, Matthias
AU - Isaksson, Marléne
AU - Niklasson, Bo
AU - Rustemeyer, Thomas
AU - Bruze, Magnus
N1 - Publisher Copyright: © 2024 The Authors. Contact Dermatitis published by John Wiley & Sons Ltd.
PY - 2024/6
Y1 - 2024/6
N2 - Background: Quantitative risk assessment (QRA) for skin sensitization is used to derive safe use levels of sensitising fragrance ingredients in products. Post-marketing surveillance of the prevalence of contact allergy to these ingredients provides relevant data to help evaluate the performance of these measures. Objectives: To determine a suitable patch test concentration for five fragrance materials that had hitherto not been tested on a regular basis. These concentrations are then to be used in a surveillance study with patch testing consecutive patients over an extended monitoring period. Materials and Methods: Furaneol, CAS.3658-77-3; trans-2-hexenal, CAS.6728-26-3; 4,8-dimethyl-4,9-decadienal, CAS.71077-31-1; longifolene, CAS.475-20-7; benzaldehyde, CAS.10052-7, were patch tested with other fragrance allergens in four clinics. Patch testing was conducted in three rounds, starting with the lowest concentrations of the five ingredients. The doses were increased in the subsequent rounds if no late-appearing positive reactions and virtually no irritant reactions were reported. Results: Overall, 373 patients were tested. No positive allergic reaction was reported to the five ingredients. Patch test results of other fragrance allergens are reported. Conclusions: The highest test concentrations are each considered safe for patch testing consecutive patients. Further surveillance based on these preparations will evaluate the hypothesis that QRA-driven consumer product levels of these fragrances can prevent sensitization.
AB - Background: Quantitative risk assessment (QRA) for skin sensitization is used to derive safe use levels of sensitising fragrance ingredients in products. Post-marketing surveillance of the prevalence of contact allergy to these ingredients provides relevant data to help evaluate the performance of these measures. Objectives: To determine a suitable patch test concentration for five fragrance materials that had hitherto not been tested on a regular basis. These concentrations are then to be used in a surveillance study with patch testing consecutive patients over an extended monitoring period. Materials and Methods: Furaneol, CAS.3658-77-3; trans-2-hexenal, CAS.6728-26-3; 4,8-dimethyl-4,9-decadienal, CAS.71077-31-1; longifolene, CAS.475-20-7; benzaldehyde, CAS.10052-7, were patch tested with other fragrance allergens in four clinics. Patch testing was conducted in three rounds, starting with the lowest concentrations of the five ingredients. The doses were increased in the subsequent rounds if no late-appearing positive reactions and virtually no irritant reactions were reported. Results: Overall, 373 patients were tested. No positive allergic reaction was reported to the five ingredients. Patch test results of other fragrance allergens are reported. Conclusions: The highest test concentrations are each considered safe for patch testing consecutive patients. Further surveillance based on these preparations will evaluate the hypothesis that QRA-driven consumer product levels of these fragrances can prevent sensitization.
KW - 4,8-dimethyl-4,9-decadienal (CAS 71077-31-1)
KW - allergic contact dermatitis
KW - benzaldehyde (CAS 100–52-7)
KW - fragrance contact allergy
KW - furaneol (CAS 3658-77-3)
KW - longifolene (CAS 475–20-7)
KW - quantitative risk assessment
KW - skin sensitization
KW - trans-2-hexenal (CAS 6728-26-3)
UR - http://www.scopus.com/inward/record.url?scp=85186483590&partnerID=8YFLogxK
U2 - 10.1111/cod.14525
DO - 10.1111/cod.14525
M3 - Article
C2 - 38387040
SN - 0105-1873
VL - 90
SP - 566
EP - 573
JO - Contact dermatitis
JF - Contact dermatitis
IS - 6
ER -